LU91391I2 - "La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" Cervarix - Google Patents

"La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" Cervarix

Info

Publication number
LU91391I2
LU91391I2 LU91391C LU91391C LU91391I2 LU 91391 I2 LU91391 I2 LU 91391I2 LU 91391 C LU91391 C LU 91391C LU 91391 C LU91391 C LU 91391C LU 91391 I2 LU91391 I2 LU 91391I2
Authority
LU
Luxembourg
Prior art keywords
cervarix
recombinant
combination
human papillomavirus
papillomavirus type
Prior art date
Application number
LU91391C
Other languages
English (en)
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26703787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91391(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/028,517 external-priority patent/US8062642B1/en
Application filed by Univ Rochester filed Critical Univ Rochester
Publication of LU91391I2 publication Critical patent/LU91391I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LU91391C 1993-03-09 2007-12-14 "La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" Cervarix LU91391I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/028,517 US8062642B1 (en) 1993-03-09 1993-03-09 Production of papillomavirus capsid protein and virus-like particles
US20730994A 1994-03-07 1994-03-07
PCT/US1994/002443 WO1994020137A1 (fr) 1993-03-09 1994-03-08 Production de proteine de capside de virus du papillome humain et particules de type viral

Publications (1)

Publication Number Publication Date
LU91391I2 true LU91391I2 (fr) 2008-02-14

Family

ID=26703787

Family Applications (3)

Application Number Title Priority Date Filing Date
LU91313C LU91313I2 (fr) 1993-03-09 2007-02-21 Combinaison de particules viroides de la protéine L1 recombinante du papillomavirus de type 6, 11, 16 et 18
LU91392C LU91392I2 (fr) 1993-03-09 2007-12-14 "La particule viroïde de la protéine L1 recombinante du papillomavirus humain de type 16" - Cervarix
LU91391C LU91391I2 (fr) 1993-03-09 2007-12-14 "La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" Cervarix

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LU91313C LU91313I2 (fr) 1993-03-09 2007-02-21 Combinaison de particules viroides de la protéine L1 recombinante du papillomavirus de type 6, 11, 16 et 18
LU91392C LU91392I2 (fr) 1993-03-09 2007-12-14 "La particule viroïde de la protéine L1 recombinante du papillomavirus humain de type 16" - Cervarix

Country Status (13)

Country Link
EP (3) EP1618888B1 (fr)
JP (4) JPH08507685A (fr)
AT (3) ATE492289T1 (fr)
AU (3) AU688759C (fr)
CA (1) CA2157932C (fr)
DE (9) DE69434383T2 (fr)
DK (2) DK1618888T3 (fr)
ES (3) ES2263405T3 (fr)
FR (1) FR11C0022I2 (fr)
LU (3) LU91313I2 (fr)
NL (3) NL300265I2 (fr)
PT (2) PT688227E (fr)
WO (1) WO1994020137A1 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000085I1 (de) 1991-07-19 2008-03-27 Univ Queensland St Lucia Polynukleotidabschnitt des HPV16-Genoms
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
DE122007000093I1 (de) * 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
AU4727296A (en) * 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
ES2213185T3 (es) * 1995-11-15 2004-08-16 MERCK & CO., INC. Particulas de tipo virus hpv11 sinteticas.
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
JP2001506485A (ja) * 1996-10-04 2001-05-22 メルク エンド カンパニー インコーポレーテッド 合成ｈｐｖ１６ウイルス様粒子
WO1998025646A1 (fr) * 1996-12-09 1998-06-18 Merck & Co., Inc. Particules synthetiques de nature virale de type hpv16
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
JP4746819B2 (ja) * 2000-09-18 2011-08-10 メディミューン，エルエルシー ワクチンの免疫原性を測定する試験管内検定
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
DE60236806D1 (de) 2001-08-13 2010-08-05 Univ Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006065166A1 (fr) * 2005-07-26 2006-06-22 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Composition de traitement et de prevention de l'infection de l'humain par le papillomavirus sur la base de la proteine l1 et des peptides de la proteine e7
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
DK2154147T3 (en) 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
CN101343315B (zh) 2007-05-29 2012-06-13 厦门大学 截短的人乳头瘤病毒6型l1蛋白
DK2910566T5 (en) 2007-05-29 2016-11-07 Univ Xiamen Truncated L1 protein of human papillomavirus 11
WO2009092113A2 (fr) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methodes et compositions d'administration de vaccins dans un epithelium rompu
WO2010079505A2 (fr) 2008-05-26 2010-07-15 Cadila Healthcare Limited Vaccin combine rougeole-papillome humain
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
WO2010112533A1 (fr) * 2009-04-03 2010-10-07 Deutsches Krebsforschungszentrum Augmentation de la production de particules analogues au papillomavirus avec un système d'expression de baculovirus modifié
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
EP3242135B1 (fr) 2010-04-08 2020-07-01 University of Pittsburgh - Of the Commonwealth System of Higher Education Analyse de cellules présentatrices d'antigène des lymphocytes b
EP3632463A1 (fr) 2011-04-08 2020-04-08 Immune Design Corp. Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
WO2013119856A1 (fr) 2012-02-07 2013-08-15 Infectious Disease Research Institute Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
CA2866582A1 (fr) 2012-03-18 2013-09-26 Brigitte Desiree Alberte Colau Procede de vaccination contre le papillomavirus humain
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
WO2014066443A1 (fr) 2012-10-23 2014-05-01 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
EP2986303B1 (fr) 2013-04-18 2020-02-26 Immune Design Corp. Monothérapie par gla pour une utilisation dans le traitement du cancer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
CN108885212B (zh) 2016-02-22 2022-05-31 勃林格殷格翰维特梅迪卡有限公司 固定生物分子的方法
BR112018073676B1 (pt) 2016-05-16 2023-10-03 University Of Virginia Patent Foundation Lipossomas peguilados e métodos de uso
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
CA3023271A1 (fr) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoparticules d'alun contenant un agent d'encollage
US11141377B2 (en) 2017-06-15 2021-10-12 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
CA3078223A1 (fr) 2017-09-08 2019-03-14 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procedes d'utilisation
WO2020243115A1 (fr) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition et procédé de séchage par atomisation d'une émulsion de vaccin et d'adjuvant
WO2022051022A1 (fr) 2020-09-04 2022-03-10 Infectious Disease Research Institute Arn co-lyophilisé et support lipidique nanostructuré
JP2024506364A (ja) 2021-02-11 2024-02-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖワクチンの製造
EP4583841A1 (fr) 2022-09-09 2025-07-16 Access to Advanced Health Institute Composition de vaccin immunogène incorporant une saponine
CN116375816B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
NZ232913A (en) * 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
DE122007000085I1 (de) * 1991-07-19 2008-03-27 Univ Queensland St Lucia Polynukleotidabschnitt des HPV16-Genoms

Also Published As

Publication number Publication date
JP2010099091A (ja) 2010-05-06
ES2263405T1 (es) 2006-12-16
NL300265I1 (nl) 2007-05-01
ES2242955T3 (es) 2005-11-16
ATE494005T1 (de) 2011-01-15
DE69434383D1 (de) 2005-06-30
JP4486075B2 (ja) 2010-06-23
AU688759C (en) 2006-12-21
FR11C0022I1 (fr) 2011-05-08
DE05075889T1 (de) 2006-10-05
EP0688227B1 (fr) 2005-05-25
JP5386392B2 (ja) 2014-01-15
ES2242955T4 (es) 2010-04-12
PT1618888E (pt) 2011-04-08
DK0688227T3 (da) 2005-06-27
CA2157932C (fr) 2011-10-11
AU6443694A (en) 1994-09-26
DE122007000090I1 (de) 2008-03-27
JP2007075117A (ja) 2007-03-29
AU2007201006B2 (en) 2010-07-01
DK1618888T3 (da) 2011-04-04
DE69435332D1 (de) 2011-02-17
EP0688227A1 (fr) 1995-12-27
ATE492289T1 (de) 2011-01-15
CA2157932A1 (fr) 1994-09-15
DE122011100018I1 (de) 2011-11-17
DE05075369T1 (de) 2006-11-16
EP0688227A4 (fr) 1996-05-29
PT688227E (pt) 2005-10-31
DE122007000014I1 (de) 2007-05-24
AU2007201005B2 (en) 2010-06-10
DE69434383T2 (de) 2005-11-24
EP1618888A1 (fr) 2006-01-25
AU2007201005A1 (en) 2007-03-29
NL300309I1 (nl) 2008-02-01
JP2010148514A (ja) 2010-07-08
ES2263406T3 (es) 2011-06-06
DE69435331D1 (de) 2011-02-03
FR11C0022I2 (fr) 2012-08-03
JPH08507685A (ja) 1996-08-20
LU91313I2 (fr) 2007-04-23
WO1994020137A1 (fr) 1994-09-15
ES2263406T1 (es) 2006-12-16
AU2007201006A1 (en) 2007-03-29
EP1588713A1 (fr) 2005-10-26
ATE296111T1 (de) 2005-06-15
AU688759B2 (en) 1998-03-19
NL300265I2 (nl) 2008-05-01
NL300309I2 (nl) 2008-03-03
NL300310I1 (nl) 2008-02-01
HK1082206A1 (en) 2006-06-02
JP5306251B2 (ja) 2013-10-02
EP1618888B1 (fr) 2011-01-05
ES2263405T3 (es) 2011-04-20
EP1588713B1 (fr) 2010-12-22
DE122007000089I1 (de) 2008-03-27
LU91392I2 (fr) 2008-02-14
HK1082196A1 (en) 2006-06-02

Similar Documents

Publication Publication Date Title
LU91391I2 (fr) "La combinaison de particules viroïdes de la protéine L1 recombinante du papillomavirus humain de types 16 et 18" Cervarix
DK0809700T3 (da) Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf
DE69535018D1 (de) Papillomavirus vakzine
EA199700281A1 (ru) Молекула днк, кодирующая белок l1 вируса папилломы типа 11 чепловека, экспрессирующий вектор, способ получения очищенных вирусоподобных частиц
WO1997004099A3 (fr) Papillomavirus, agents de depistage de ceux-ci et de therapie de maladies causees par ces virus
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
DE69829174D1 (de) Exprimierung eines modifiziertem "foamy virus envelope protein" (hüllenprotein)
DE50015132D1 (de) Chimäre virus-ähnliche partikel bzw. chimäre capsomere von bpv (bovine papilloma virus)